Brakke Consulting’s latest multi-client study takes an in-depth look at pain management products for dogs and cats.
The pain management market is one of the largest segments in companion animal health,” said Lynn Fondon DVM MBA, senior consultant of Brakke Consulting. “Sales of small animal analgesics have increased 30-fold since the introduction of Rimadyl, the first of the new-generation NSAIDs, in 1996.”
The study, Pain Management Products for Dogs and Cats, profiles the veterinary market for analgesics, both veterinary and human products, as well as nutritional supplements, therapeutic diets for joint support, and complementary therapies. The report includes an overview of pain management in veterinary medicine, leading product sales and pricing, and a discussion of new and developing products including Galliprant, as well as a number of novel molecules. This year’s report also includes a discussion of the role of cannabinoids in veterinary medicine, as well as the impact that the human opioid abuse crisis is having on veterinary use of opioids. The report features a survey of 370 small animal veterinarians probing their use of analgesics for both acute and chronic pain.
“Our veterinary survey found that veterinarians are generally satisfied with the available products for dogs, but feel there is a need for safer analgesics for cats, particularly those that can be used long-term,” commented Dr. Fondon.
The 2019 Pain Management Products for Dogs and Cats report is available from Brakke Consulting for $5,750. For more information, interested companies should contact email@example.com.
About Brakke Consulting
For over 30 years, Brakke Consulting has offered comprehensive solutions for the animal health industry, including market research, new business development, product evaluation, and distribution strategies. The company is known for its syndicated market studies, providing strategic, timely information for the industry. Learn more about the company at www.BrakkeConsulting.com.